ANO1 and gastric cancer: In the genomic profiling‐based GI cancer MSK dataset (Figure S1C, Supporting Information), ANO1 amplified in 31.25% (5/16) patients and was drastically correlated with poor irPFS/irOS (Figure 1C), whose indication to adverse immunotherapeutic outcome retained for GC (Figure S1D, Supporting Information).